413 reports of this reaction
1.6% of all AVAPRITINIB reports
#14 most reported adverse reaction
LACRIMATION INCREASED is the #14 most commonly reported adverse reaction for AVAPRITINIB, manufactured by Blueprint Medicines Corporation. There are 413 FDA adverse event reports linking AVAPRITINIB to LACRIMATION INCREASED. This represents approximately 1.6% of all 25,335 adverse event reports for this drug.
Patients taking AVAPRITINIB who experience lacrimation increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LACRIMATION INCREASED is a less commonly reported adverse event for AVAPRITINIB, but still significant enough to appear in the safety profile.
In addition to lacrimation increased, the following adverse reactions have been reported for AVAPRITINIB:
The following drugs have also been linked to lacrimation increased in FDA adverse event reports:
LACRIMATION INCREASED has been reported as an adverse event in 413 FDA reports for AVAPRITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
LACRIMATION INCREASED accounts for approximately 1.6% of all adverse event reports for AVAPRITINIB, making it a notable side effect.
If you experience lacrimation increased while taking AVAPRITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.